August 2026 European Growth Companies With Strong Insider Ownership
As the European market navigates through global bond sell-offs and inflationary pressures, the pan-European STOXX Europe 600 Index has seen a slight decline, reflecting broader economic uncertainties. In this environment, growth companies with strong insider ownership can be particularly appealing as they often signal confidence from those closest to the company's operations and strategic direction.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| MilDef Group (OM:MILDEF) | 10.3% | 30.9% |
| Kuros Biosciences (SWX:KURN) | 25.9% | 58.6% |
| KebNi (OM:KEBNI B) | 11.8% | 105.2% |
| Gold Road International (OB:GOLDR) | 35.9% | 86% |
| Envipco Holding (ENXTAM:ENVI) | 15.4% | 100.4% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.5% | 60.7% |
| CD Projekt (WSE:CDR) | 35.2% | 39.6% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.2% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 52% |
Let's review some notable picks from our screened stocks.
Atea (OB:ATEA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Atea ASA offers IT infrastructure and related solutions to businesses and public sector organizations across the Nordic countries and Baltic regions, with a market cap of NOK19.57 billion.
Operations: The company's revenue segments are distributed across Norway (NOK10.16 billion), Sweden (NOK15.52 billion), Denmark (NOK8.65 billion), Finland (NOK3.58 billion), the Baltics (NOK2.15 billion), and Group Shared Services (NOK13.69 billion).
Insider Ownership: 28.6%
Atea ASA demonstrates strong growth potential with its recent earnings report showing significant increases in both sales and net income, highlighting a robust performance. The company's revenue is forecast to grow at 6.6% annually, outpacing the Norwegian market's growth rate. However, while earnings are expected to grow at 8.5% per year, they remain below the threshold for significant growth. Trading at a substantial discount to its estimated fair value suggests potential for capital appreciation despite limited insider trading activity recently.
- Navigate through the intricacies of Atea with our comprehensive analyst estimates report here.
- Our valuation report unveils the possibility Atea's shares may be trading at a discount.
Mowi (OB:MOWI)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Mowi ASA is a seafood company that produces and sells Atlantic salmon products globally, with a market capitalization of NOK107.25 billion.
Operations: Mowi ASA generates revenue primarily from its Farming segment (€3.81 billion), Sales & Marketing - Markets (€4.36 billion), Sales and Marketing - Consumer Products (€3.94 billion), and Feed operations (€992 million).
Insider Ownership: 15.9%
Mowi ASA's recent earnings report revealed a net loss despite increased sales, highlighting challenges amidst its growth trajectory. The company's revenue is forecast to grow at 6.4% annually, surpassing the Norwegian market rate. Earnings are expected to rise significantly at 22.3% per year, indicating strong potential for profit expansion. However, Mowi carries a high debt level and trades well below its estimated fair value, suggesting room for capital appreciation without substantial insider trading activity recently.
- Dive into the specifics of Mowi here with our thorough growth forecast report.
- Our comprehensive valuation report raises the possibility that Mowi is priced lower than what may be justified by its financials.
BioArctic (OM:BIOA B)
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (publ) is a Swedish company that develops biological drugs for central nervous system disorders, with a market cap of SEK29.78 billion.
Operations: BioArctic AB generates revenue primarily from its biotechnology segment, which amounted to SEK1.15 billion.
Insider Ownership: 32.2%
BioArctic's earnings are forecast to grow significantly at 62.3% annually, outpacing the Swedish market. Despite a decline in profit margins from last year, the company is trading well below its estimated fair value. Recent FDA approval for Leqembi Iqlik enhances BioArctic's Alzheimer's treatment portfolio, offering convenient subcutaneous administration options. A strategic collaboration with Eli Lilly brings potential milestone payments up to US$770 million, bolstering BioArctic's growth prospects in neurodegeneration therapies.
- Take a closer look at BioArctic's potential here in our earnings growth report.
- Our comprehensive valuation report raises the possibility that BioArctic is priced higher than what may be justified by its financials.
Turning Ideas Into Actions
- Investigate our full lineup of 216 Fast Growing European Companies With High Insider Ownership right here.
- Seeking Other Investments? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com